Conexeu Sciences Files S-1/A for 9.48M Share Resale Ahead of Nasdaq Listing

TL;DR

**Conexeu's direct listing is a high-risk gamble on preclinical tech with no guaranteed FDA path or stable market debut, so stay on the sidelines until there's real traction.**

AI Summary

Conexeu Sciences Inc. filed an S-1/A on March 26, 2026, to register the resale of up to 9,481,123 shares of common stock by existing securityholders, not to raise new capital. These shares include 750,000 from a September 15, 2024 debt settlement, 3,750,000 from a May 16, 2025 private placement, 416,667 from a May 16, 2025 business advisory agreement, and 397,789 from a Regulation Crowdfunding (Reg CF) offering that concluded on October 9, 2025, where 2,449,962 shares were sold at $2.00 per share. Additionally, 3,750,000 shares are issuable upon exercise of private placement warrants and 416,667 shares from business advisory warrants. The company, an early-stage medical device firm, is focused on developing the CXU scaffold device, a collagen-based regenerative tissue product currently in preclinical development. Conexeu aims for U.S. FDA 510(k) clearance as a Class II medical device, but the regulatory pathway is not yet determined. The company expects its common stock to begin trading on Nasdaq under the symbol "CNXU" around 2026, but warns that a public market does not currently exist and listing is not guaranteed.

Why It Matters

This S-1/A filing signals Conexeu Sciences Inc.'s intent to list on Nasdaq, providing liquidity for early investors and potentially opening the door for new capital in the future, despite not being an underwritten offering. For investors, the lack of an underwritten offering means higher potential volatility and less price stability compared to a traditional IPO. Employees and customers will watch for the successful listing and subsequent development of the CXU scaffold, which could disrupt the wound care market if it achieves FDA clearance. The competitive landscape for regenerative tissue products is intense, and Conexeu's success hinges on its ability to navigate regulatory hurdles and demonstrate clinical efficacy for its novel collagen-based technology.

Risk Assessment

Risk Level: high — The filing explicitly states, "The purchase of the securities offered by this prospectus involves a high degree of risk. You should invest in our shares of common stock only if you can afford to lose your entire investment." This is further supported by the fact that the CXU scaffold device candidate is in preclinical development and "has not been approved or cleared for marketing in any jurisdiction," indicating significant regulatory and commercialization risk. Additionally, "No public market for our common stock currently exists," and the direct listing without a firm-commitment underwritten offering could lead to higher price volatility.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative opportunity. Given the preclinical stage of its primary product, the CXU scaffold, and the absence of a firm-commitment underwritten offering, it would be prudent to wait for significant clinical milestones and FDA clearance before considering an investment. Monitor the Nasdaq listing approval and initial trading behavior for signs of market interest, but be prepared for substantial volatility.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$0

total Debt

$0

net Income

$0

eps

$0

gross Margin

N/A

cash Position

$0

revenue Growth

N/A

Key Numbers

• 9,481,123 — Shares of Common Stock (Registered for resale by securityholders)
• 750,000 — Shares of Common Stock (Issued via Debt Settlement Agreement on September 15, 2024)
• 3,750,000 — Shares of Common Stock (Issued via Private Placement on May 16, 2025)
• 416,667 — Shares of Common Stock (Issued via Business Advisory Agreement on May 16, 2025)
• 397,789 — Shares of Common Stock (Issued via Regulation Crowdfunding offering by October 9, 2025)
• 3,750,000 — Shares of Common Stock (Issuable upon exercise of Private Placement Warrants)
• 416,667 — Shares of Common Stock (Issuable upon exercise of Business Advisory Warrants)
• $2.00 — Per Share Price (For Reg CF offering, concluded October 9, 2025)
• 2,449,962 — Shares of Common Stock (Sold in the Reg CF offering)
• November 2, 2022 — Incorporation Date (Conexeu Sciences Inc. incorporated in British Columbia)

Key Players & Entities

• Conexeu Sciences Inc. (company) — Registrant and developer of CXU scaffold
• 9,481,123 shares (dollar_amount) — Total shares registered for resale
• Nasdaq Capital Market (regulator) — Intended listing exchange for common stock
• U.S. Food and Drug Administration (regulator) — Regulatory body for CXU scaffold clearance
• CXU scaffold device candidate (company) — Company's only device candidate, in preclinical development
• H.C. Wainwright & Co., LLC (company) — Financial advisor for Nasdaq listing
• September 15, 2024 (date) — Date of Debt Settlement Agreement
• May 16, 2025 (date) — Date of Private Placement and Business Advisory Agreement
• October 9, 2025 (date) — Conclusion date of Regulation Crowdfunding offering
• $2.00 (dollar_amount) — Per share price in Reg CF offering

FAQ

Risk Factors

• Uncertainty of FDA Approval Pathway [high — regulatory]: The company is developing a regenerative tissue product, the CXU scaffold device, which is in preclinical development. The specific regulatory pathway for U.S. FDA 510(k) clearance as a Class II medical device is not yet determined, introducing significant uncertainty regarding market entry and commercialization timelines.
• Lack of Established Public Market [high — market]: Conexeu Sciences Inc. anticipates its common stock to trade on Nasdaq under the symbol 'CNXU' around 2026. However, the company explicitly warns that a public market does not currently exist, and listing is not guaranteed, posing a risk to liquidity and valuation for existing and future shareholders.
• Early-Stage Product Development Risk [high — operational]: The CXU scaffold device is in the preclinical development stage. Significant risks exist in achieving successful product development, manufacturing scalability, and ultimately, market acceptance, which are critical for the company's future success.
• Dependence on Future Funding [medium — financial]: As an early-stage company with a product in preclinical development, Conexeu Sciences Inc. will likely require substantial future funding to support research, development, regulatory submissions, and commercialization efforts. The ability to secure this funding is a significant risk.
• Potential for Dilution from Warrant Exercise [medium — legal]: A substantial number of shares, 3,750,000 from private placement warrants and 416,667 from business advisory warrants, are issuable upon exercise. If exercised, these could lead to significant dilution for existing shareholders.

Industry Context

Conexeu Sciences Inc. operates in the regenerative medicine and medical device sector, a rapidly evolving field focused on tissue repair and regeneration. The market is characterized by significant innovation, long development cycles, and stringent regulatory oversight from bodies like the FDA. Key trends include the increasing demand for advanced therapies and the growing interest in collagen-based biomaterials for medical applications.

Regulatory Implications

The company's success hinges on navigating the complex U.S. FDA regulatory landscape for medical devices. The lack of a determined 510(k) pathway for its CXU scaffold device presents a substantial risk, as delays or failure to obtain clearance could prevent market entry. Compliance with evolving regulations for regenerative therapies will be critical.

What Investors Should Do

1. Monitor FDA communication and regulatory pathway determination for the CXU scaffold device.
2. Assess the company's ability to secure future funding rounds.
3. Evaluate the potential dilution from warrant exercises.
4. Track progress towards Nasdaq listing and the establishment of a public market.

Key Dates

• 2024-09-15: Debt Settlement Agreement — Resulted in the issuance of 750,000 shares of common stock.
• 2025-05-16: Private Placement and Business Advisory Agreement — Resulted in the issuance of 3,750,000 shares and 416,667 shares, respectively.
• 2025-10-09: Regulation Crowdfunding Offering Conclusion — 2,449,962 shares were sold at $2.00 per share, with 397,789 shares registered for resale from this offering.
• 2026: Anticipated Nasdaq Listing — The company expects its common stock to begin trading on Nasdaq under the symbol 'CNXU', though listing is not guaranteed.
• 2022-11-02: Company Incorporation — Conexeu Sciences Inc. was incorporated in British Columbia.

Glossary

S-1/A

An amended registration statement filed with the U.S. Securities and Exchange Commission (SEC) for the resale of securities by existing shareholders, not for raising new capital. (This filing indicates that existing investors are looking to sell their shares, and the company is facilitating this process by registering these shares.)

510(k) clearance

A premarket submission made to the U.S. Food and Drug Administration (FDA) to demonstrate that a proposed medical device is 'substantially equivalent' to a legally marketed device. (This is the primary regulatory pathway Conexeu Sciences Inc. aims for its CXU scaffold device, crucial for market entry.)

Class II medical device

Medical devices that require a moderate level of assurance of safety and effectiveness. They are subject to general controls and special controls. (The CXU scaffold device is intended to be classified as a Class II device, indicating specific regulatory requirements.)

Preclinical development

The stage of research and development that occurs before human clinical trials, involving laboratory and animal studies to assess safety and efficacy. (Conexeu's CXU scaffold device is currently in this early stage, highlighting the significant development and regulatory hurdles ahead.)

Regulation Crowdfunding (Reg CF)

A U.S. Securities and Exchange Commission (SEC) regulation that permits companies to raise capital from a broad base of investors through online crowdfunding platforms. (Conexeu utilized Reg CF to sell shares, indicating a strategy to access capital from a wider, potentially retail, investor base.)

Private Placement Warrants

Warrants issued as part of a private placement transaction, giving the holder the right to purchase shares of the company's stock at a specified price within a certain timeframe. (These warrants represent a significant number of shares (3,750,000) that could be issued, impacting future share count and dilution.)

Year-Over-Year Comparison

This S-1/A filing is primarily for the resale of existing shares and does not represent a new capital raise or a change in the company's operational or financial status since its last disclosure. Therefore, direct year-over-year comparisons of financial metrics like revenue, net income, or margins are not applicable based on this filing alone. The key focus remains on the company's early-stage development and the upcoming regulatory and market listing milestones.

Key Financial Figures

• $2.00 — enced the Reg CF offering at a price of $2.00 per share, which concluded on October 9
• $50,000 — when the Company pays the University CAD$50,000 (US$40,060) for expenses incurred and f
• $40,060 — mpany pays the University CAD$50,000 (US$40,060) for expenses incurred and fully pays t
• $136,539 — incurred and fully pays the loan of CAD$136,539 (US$98,117 as of October 31, 2024) plus
• $98,117 — d fully pays the loan of CAD$136,539 (US$98,117 as of October 31, 2024) plus accrued in
• $48,526 — ,251 Shares which had a fair value of US$48,526. On March 4, 2025, the Company paid the
• $213,795 — mpany paid the University a total of CAD$213,795 (US$148,037) in full settlement of the
• $148,037 — he University a total of CAD$213,795 (US$148,037) in full settlement of the expenses pay

Filing Documents

• forms1a.htm (S-1/A) — 2400KB
• exhibit23-1.htm (EX-23.1) — 3KB
• forms1ax001.jpg (GRAPHIC) — 46KB
• forms1ax002.jpg (GRAPHIC) — 42KB
• forms1ax003.jpg (GRAPHIC) — 7KB
• forms1axu001.jpg (GRAPHIC) — 7KB
• exhibit23-1xu001.jpg (GRAPHIC) — 6KB
• 0001062993-26-001640.txt ( ) — 2552KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 5 TERMS USED IN THIS PROSPECTUS 6 PROSPECTUS SUMMARY 7 GLOSSARY OF TECHNICAL TERMS 14

USE OF PROCEEDS

USE OF PROCEEDS 34 DIVIDEND POLICY 34 CAPITALIZATION 34

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 35

BUSINESS

BUSINESS 44 MARKET 61 GOVERNMENT REGULATION 64 MANAGEMENT 76 EXECUTIVE AND DIRECTOR COMPENSATION 85 RELATED PARTY TRANSACTIONS 94 PRINCIPAL AND REGISTERED SECURITYHOLDERS 101

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 144 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO HOLDERS OF OUR COMMON STOCK 146 SHARES ELIGIBLE FOR FUTURE SALE 151 SALE PRICE HISTORY OF OUR COMMON STOCK 153 PLAN OF DISTRIBUTION 154 INTERESTS OF NAMED EXPERTS AND COUNSEL 157 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 158 WHERE YOU CAN FIND MORE INFORMATION 158 INDEX TO FINANCIAL STATEMENTS F-1 - 4 - You should rely only on the information contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectus prepared by or on our behalf. Neither we, nor the Registered Securityholders, have authorized any other person to provide you with different or additional information. Neither we, nor the Registered Securityholders, take responsibility for, nor can we provide assurance as to the reliability of, any other information that others may provide. The Registered Securityholders are offering to sell, and seeking offers to buy, shares of their common stock only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and/or prospects may have changed since such dates. This prospectus includes industry and market data that we obtained from periodic industry publications, third-party studies and surveys, filings of public companies in our industry and internal company surveys. These sources include government and industry sources. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable. Although we believe the industry and market data to be reliable as of the date of this prospectus, this information could prove to be inaccurate. Industry and

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS Certain statements contained in this prospectus constitute "forward-looking statements." These statements appear in a number of places in this prospectus and documents included or incorporated by reference herein and include statements regarding Conexeu's intent, belief or current expectations, and that of Conexeu's officers and directors. These forward-looking statements involve known and unknown risks and uncertainties that may cause Conexeu's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as "believe", "intend", "may", "will", "should", "plans", "anticipates", "believes", "potential", "intends", "expects" and other similar expressions. These statements are based on Conexeu's current plans and are subject to risks and uncertainties, and as such Conexeu's actual future activities and results of operations may be materially different from those set forth in the forward-looking statements. Any or all of the forward-looking statements in this prospectus may turn out to be inaccurate and as such, you should not place undue reliance on these forward-looking statements. Conexeu has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. The forward-looking statements can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and assumptions due to a number of factors. Important factors that you should also consider, include, but are not limited to, the factors discussed under "Risk Factors" in this prospectus. In addition, Conexeu cannot assess the impact of each factor on its intended business or the extent t

View Full Filing

View this S-1/A filing on SEC EDGAR